¥ 739
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Overvalued vs peers
Data is available to registered users only
Data is available to registered users only
About
StemCell Institute Inc. provides specialized stem cell banking services throughout Japan. In addition to its core preservation activities, the company is deeply involved in the research and development of medical therapies that utilize stem cells, and it also offers banking solutions for blood vessel cells. Founded in 1999, StemCell Institute Inc. is headquartered in Tokyo, Japan, and operates as a subsidiary of Trim Medical Holdings Inc.
Company Valuation
Based on key historical and expected multiples, the stock is overvalued relative to its peers. In particular, the stock is overpriced on P/E, of fair value on EV/EBITD.
Data is available to registered users only